<?xml version="1.0" encoding="UTF-8"?>

<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>
<channel>
    	<title>IJPRS/V2/I4/00230 - 15/12/2013</title>

	<item>
		<title>Analytical Method Development and Validation of Dasatinib in its Pharmaceutical Dosage Form by UPLC with Forced Degradation Studies</title>
		
		<description><![CDATA[<h5>Author's Affiliation</h5>
		                                                <p></p>
		                                                <hr/>
                                                    	<h5>Abstract</h5>
		                                                <p>A simple, accurate, precise, sensitive, rapid Ultra Performance Liquid chromatography (UPLC) method has been developed and validated for determination of Dasatinib in its pharmaceutical dosage form. Chromatographic separation was achieved on a Waters Acquity BEH C18 column(100 ×2.1mm,1.7), by a mobile phase consisted of Tri Ethyl Amine buffer(pH 6±0.05,maintained with ortho phosphoric acid) and Acetonitrile in 30:70(V/V) ratio with a flow rate of 0.8 ml/min. The detection wavelength was set at 322 nm. Dasatinib was subjected to different stress conditions like acid, alkali, and peroxide, thermal and checked for its specificity, degradation &amp; stability. The method was linear (r = 0.999) at a concentration range of 5-25 μg/ml. The intra and inter day precisions were satisfactory; the relative standard deviations did not exceed 2%. The accuracy of the method was proved; the mean recovery of Dasatinib was 99.04-101.58%<strong>.</strong> The proposed method has high throughput as the analysis involved short run-time (2.5 mins). The method met the ICH/FDA regulatory requirements. The results demonstrated that the method can be applied successfully for routine use in quality control industry laboratories.</p>
                                                    	<hr/>
                                                        <h5>Keywords</h5>
                                                         <p>Dasatinib, UPLC, validation, forced degradation</p>
                                                         
                                                    	                                                    	<hr/>
                                                         <h5>Cite This Article</h5>
                                                         <p>Rao, K. N. V., Srivani, P., Raja, M. A., Banji, D., &amp; Kumar, D. S. (2013). Analytical Method Development and Validation of Dasatinib in its Pharmaceutical Dosage Form by UPLC with Forced Degradation Studies. <em>International Journal for Pharmaceutical Research Scholars (IJPRS), 2(4),</em> 221-227.</p>                                                         <hr/>
                                                         <p><a class="a2a_button_facebook" href="https://www.addtoany.com/add_to/facebook?linkurl=https%3A%2F%2Fwww.ijprs.com%2Farticle%2Fanalytical-method-development-and-validation-of-dasatinib-in-its-pharmaceutical-dosage-form-by-uplc-with-forced-degradation-studies%2F&amp;linkname=Analytical%20Method%20Development%20and%20Validation%20of%20Dasatinib%20in%20its%20Pharmaceutical%20Dosage%20Form%20by%20UPLC%20with%20Forced%20Degradation%20Studies" title="Facebook" rel="nofollow noopener" target="_blank"></a><a class="a2a_button_twitter" href="https://www.addtoany.com/add_to/twitter?linkurl=https%3A%2F%2Fwww.ijprs.com%2Farticle%2Fanalytical-method-development-and-validation-of-dasatinib-in-its-pharmaceutical-dosage-form-by-uplc-with-forced-degradation-studies%2F&amp;linkname=Analytical%20Method%20Development%20and%20Validation%20of%20Dasatinib%20in%20its%20Pharmaceutical%20Dosage%20Form%20by%20UPLC%20with%20Forced%20Degradation%20Studies" title="Twitter" rel="nofollow noopener" target="_blank"></a><a class="a2a_dd addtoany_share_save addtoany_share" href="https://www.addtoany.com/share#url=https%3A%2F%2Fwww.ijprs.com%2Farticle%2Fanalytical-method-development-and-validation-of-dasatinib-in-its-pharmaceutical-dosage-form-by-uplc-with-forced-degradation-studies%2F&#038;title=Analytical%20Method%20Development%20and%20Validation%20of%20Dasatinib%20in%20its%20Pharmaceutical%20Dosage%20Form%20by%20UPLC%20with%20Forced%20Degradation%20Studies" data-a2a-url="https://www.ijprs.com/article/analytical-method-development-and-validation-of-dasatinib-in-its-pharmaceutical-dosage-form-by-uplc-with-forced-degradation-studies/" data-a2a-title="Analytical Method Development and Validation of Dasatinib in its Pharmaceutical Dosage Form by UPLC with Forced Degradation Studies"></a></p>]]>
        </description>
		<link>https://www.ijprs.com/article/analytical-method-development-and-validation-of-dasatinib-in-its-pharmaceutical-dosage-form-by-uplc-with-forced-degradation-studies/</link>
		<author>Rao, K. N. V., Srivani, P., Raja, M. A., Banji, D., Kumar, D. S.        </author>

		<pdflink>http://www.ijprs.com/wp-content/uploads/2018/09/IJPRS-V2-I4-00230.pdf</pdflink>

	</item>
</channel>
</rss>
